XBiotech
XBIT
44 hedge funds and large institutions have $13M invested in XBiotech in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 8 closing their positions.
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
1.67% less ownership
Funds ownership: 11% → 9.33% (-1.7%)
2% less funds holding
Funds holding: 45 → 44 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
23% less capital invested
Capital invested by funds: $17M → $13M (-$3.94M)
81% less call options, than puts
Call options by funds: $132K | Put options by funds: $708K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$166K |
| 2 |
Goldman Sachs
New York
|
+$132K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$112K |
| 4 |
Millennium Management
New York
|
+$91.4K |
| 5 |
Morgan Stanley
New York
|
+$63.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.34M |
| 2 |
Swiss National Bank
Zurich,
Switzerland
|
-$138K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$112K |
| 4 |
ProShare Advisors
Bethesda,
Maryland
|
-$93K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$91.2K |
XBIT Hedge Fund Activity: Q4 2017 in Review
44 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2017, worth a combined $13M — down 23% from $17M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of XBIT and 7 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 12 added.
The largest buyer was Paloma Partners, opening a new position worth an estimated $166K. The largest seller was BlackRock, cutting an estimated $2.34M.
- 44 institutional investors held XBiotech (XBIT) as of Q4 2017, down from 45 in Q3 2017.
- Funds reported $13M of XBiotech stock for Q4 2017, down 23% quarter-over-quarter.
- 7 funds opened new XBiotech positions in Q4 2017 and 8 closed out, a net change of -1 holder.
- The largest XBiotech buyer in Q4 2017 was Paloma Partners, an estimated $166K added.
- The largest XBiotech seller in Q4 2017 was BlackRock, an estimated $2.34M sold.
Based on aggregated 13F filings for Q4 2017.